We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial.
- Authors
Ohsawa, Isao; Honda, Daisuke; Suzuki, Yusuke; Fukuda, Tomoo; Kohga, Keisuke; Morita, Eishin; Moriwaki, Shinichi; Ishikawa, Osamu; Sasaki, Yoshihiro; Tago, Masaki; Chittick, Greg; Cornpropst, Melanie; Murray, Sharon C.; Dobo, Sylvia M.; Nagy, Eniko; Van Dyke, Sharon; Reese, Lacy; Best, Jessica M.; Iocca, Heather; Collis, Phil
- Abstract
Background: With no approved treatments in Japan for the prevention of hereditary angioedema (HAE) attacks, there is a significant unmet need for long‐term prophylactic therapies for Japanese patients with HAE. Berotralstat (BCX7353) is an oral, once‐daily, highly selective inhibitor of plasma kallikrein in development for prophylaxis of angioedema attacks in HAE patients. Methods: APeX‐J is a phase 3, randomized, double‐blind, placebo‐controlled, parallel‐group, 3‐part trial conducted in Japan (University Hospital Medical Information Network identifier, UMIN000034869; ClinicalTrials.gov identifier, NCT03873116). Patients with a clinical diagnosis of type 1 or 2 HAE underwent a prospective run‐in period of 56 days to determine eligibility, allowing enrollment of those with ≥2 expert‐confirmed angioedema attacks. Patients were randomly assigned (1:1:1) and stratified by baseline attack rate (≥2 vs. <2 expert‐confirmed attacks/month between screening and randomization) to receive once‐daily berotralstat 110 mg, berotralstat 150 mg, or placebo. The primary endpoint was the rate of expert‐confirmed angioedema attacks during dosing in the 24‐week treatment period. Results: Nineteen patients were randomized to receive once‐daily berotralstat 110 mg (n = 6), berotralstat 150 mg (n = 7), or placebo (n = 6). Treatment with berotralstat 150 mg significantly reduced HAE attacks relative to placebo (1.11 vs. 2.18 attacks/month, p =.003). The most frequently reported treatment‐emergent adverse events (TEAEs) in berotralstat‐treated patients (n = 13) were nasopharyngitis (n = 4, 31%), abdominal pain, cough, diarrhea, and pyrexia (n = 2 each, 15%). Conclusions: Orally administered, once‐daily berotralstat 150 mg significantly reduced the frequency of HAE attacks and was safe and well tolerated, supporting its use as a prophylactic therapy in patients with type 1 or 2 HAE in Japan.
- Subjects
JAPAN; ANGIONEUROTIC edema; JAPANESE people; DIAGNOSIS; ABDOMINAL pain; INFORMATION networks; COUGH; CLUSTER headache
- Publication
Allergy, 2021, Vol 76, Issue 6, p1789
- ISSN
0105-4538
- Publication type
Article
- DOI
10.1111/all.14670